Mitsubishi Tanabe completes Choseido acquisition
This article was originally published in Scrip
Executive Summary
Mitsubishi Tanabe Pharmaceutical(MTP) has completed its acquisition of the small Japanese generics firm Choseido Pharmaceutical. MTP raised its ownership of the firm from 10% to 51% through the purchase of 697,000 shares, in a deal first announced earlier this year (Scrip Online, May 8th, 2008). The price was not disclosed but MTP said the impact on its results would be minor. Choseido had sales of ¥5.6 billion ($51.4 million) in the last fiscal year, and will manufacture products for sale through MTP's new generics marketing operation, Tanabe Seiyaku Hanbai.
You may also be interested in...
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: the shifting sands of pharma R&D; big pharma oncology strategies; semaglutide’s promise in heart failure; AstraZeneca looks to multiple cancer modalities; and an interview with Astellas’s chief strategy officer.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: Genmab buys into ADCs; Roivant set to take on AbbVie in uveitis; Ipsen signs firs ADC pact; South Korea looks to build biotech momentum; and the end of the road for Acorda.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: Merck & Co progresses cardiovascular strategy; Novo purchase builds heart failure presence; CRL setbacks for Regeneron; ITF faces challenging Duchenne field; and AbbVie needs to freshen up.